Top Factor Driving Genomic Biomarker Market Growth in 2025: Impact of Chronic Disease Prevalence on Genomic Biomarker Market Growth

How Big Is the Genomic Biomarker Market Expected to Be, and What Will Its Growth Rate Be?
The size of the genomic biomarker market has seen a swift expansion in recent times. It's expected to increase from $8.4 billion in 2024 to $9.9 billion in 2025, growing at a compound annual growth rate (CAGR) of 18.0%. The historic period growth can be credited to the growing awareness about genetic disorders, heightened demand for targeted therapies, amplified usage of big data in genomics, the development of global genomic databases, and the increase in biomarker-based clinical trials.

In the upcoming years, the genomic biomarker market is predicted to experience a swift expansion. It's projected to reach a value of $18.93 billion by 2029, with a compound annual growth rate (CAGR) of 17.6%. This growth during the projected period can be credited to an increasing emphasis on individualized medication availability, a surge in cardiovascular disease instances, a rise in patients with neurological diseases, heightened investment in genomic research, and an uptick in personalized nutrition adoption. Key trends for the forecast period include technological progression, digital health evolution, the incorporation of artificial intelligence, machine learning, and the rise of personalized medicine.

What Are the Primary Growth Drivers for the Genomic Biomarker Market?
The growth of the genomic biomarker market is anticipated to accelerate due to the escalating incidence of chronic illnesses. These are sustained health issues that tend to endure for extended periods and commonly evolve gradually. The burgeoning occurrence of such diseases is accredited to the aging populace and the increasing cases of lifestyle-related illnesses such as diabetes and obesity. Genomic biomarkers offer the advantage of early detection and customized prevention maneuvers for chronic diseases by recognizing genetic susceptibilities and adjusting interventions. This initiative aids in diminishing prevalence by focusing on individuals at risk before the disease actually manifests. For example, in September 2023, the World Health Organization (WHO), a Switzerland-based international body, revealed that 41 million deaths globally each year, amounting to 74% of all deaths, are due to chronic diseases. This includes 17.9 million deaths from heart-related diseases, 9.3 million from cancer, 4.1 million from chronic lung diseases, and 2.0 million from diabetes. Consequently, the rising incidence of chronic diseases propels the expansion of the genomic biomarkers market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp

Who Are the Dominant Companies Influencing Genomic Biomarker Market Trends?
Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.

Who Are the Dominant Companies Influencing Market Trends?
Key players in the genomic biomarker market are prioritizing the development of cutting-edge products like state-of-the-art liquid biopsy assays for extensive genomic profiling of solid tumors. A liquid biopsy assay is a diagnostic tool that examines genetic matter, usually circulating tumor DNA (ctDNA), from a blood sample to identify and track cancer. Genomic biomarkers yield data regarding specific mutations, the expression levels of certain genes, or other genetic variations linked to cancer. For instance, in November 2023, Illumina Inc., an American biotech firm, unveiled a sophisticated liquid biopsy assay called TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) designed for extensive genomic profiling of solid tumors. This assay improves analytical sensitivity by identifying low-frequency variants using only 20 ng of cell-free DNA, a reduction from 30 ng. It produces results within four days, significantly speeding up genomic profiling compared to conventional methods. The automated and streamlined processes are sure to facilitate laboratory integration and increase efficiency.

What Are the Different Segmentations in the Genomic Biomarker Market?
The genomic biomarker market covered in this report is segmented -

1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users

Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report

Which Region Is at the Forefront of the Genomic Biomarker Market?
North America was the largest region in the genomic biomarker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Genomic Biomarker Global Market Report?

- Market Size Analysis: Analyze the genomic biomarker Market Size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the genomic biomarker market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall genomic biomarker market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the genomic biomarker market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20557

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.